Supplements / hidden drug ingredients
A May 2026 recall for WAP Sensual Enhancement capsules is a useful example because the issue is plain: a product marketed as a dietary supplement was found to contain undeclared prescription-drug ingredients.
FDA posted a company announcement on May 18, 2026 for Best Supplements Best Prices. The company announced a consumer-level recall of all lots of WAP Sensual Enhancement capsules after FDA analysis found undeclared sildenafil, tadalafil, and flibanserin.
That recall sits in a familiar enforcement lane. Products sold as sexual enhancement supplements can cross from supplement marketing into drug-risk territory when FDA testing finds active pharmaceutical ingredients that are not declared on the label. The buyer may think they are purchasing a supplement. FDA's source record describes a product with ingredients used in FDA-approved prescription drugs.
The recall announcement names three undeclared ingredients. Sildenafil and tadalafil are ingredients in FDA-approved prescription drugs used to treat erectile dysfunction. FDA's posted announcement says these ingredients can interact with nitrates, including nitroglycerin, and can lower blood pressure to unsafe levels. The announcement also notes that consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.
The third ingredient, flibanserin, is the active ingredient in an FDA-approved prescription drug used to treat low sexual desire in women. The recall announcement says flibanserin can cause drowsiness, sedation, low blood pressure, and fainting, with special concern when combined with alcohol.
FDA's page also gives operational detail: WAP Sensual Enhancement, UPC 80174 00462, was marketed as a dietary supplement for sexual enhancement and distributed nationwide in the United States through eBay. The company announcement says customers were being notified by email and refunds were being arranged.
FDA maintains a sexual enhancement and energy product notification page for consumers. The page warns that sellers often advertise products promoted for sexual enhancement or sexual dysfunction as dietary supplements, foods, or all-natural treatments. FDA also says sellers offer them online and in stores, with positive reviews and social media circulation.
That makes the signal useful for more than consumer safety teams. Supplement brands, marketplace trust-and-safety teams, compliance consultants, affiliate operators, and retailers all have a reason to monitor this category. The same public FDA page that informs consumers can also help operators see which product types, claims, and sales channels keep producing source-backed risk.
A hidden-drug-ingredient recall can create several problems at once. The label issue is obvious, but the commercial issue can be just as sharp. A marketplace listing, refund process, customer email, payment processor review, affiliate page, or distributor relationship can become part of the response work once the recall is public.
There is also a claims problem nearby. FDA's April 29, 2026 warning letter to OptiHealth Products shows a separate supplement pattern: public web pages and social media links can help establish intended use as a drug when the claims discuss cure, mitigation, treatment, or prevention of disease. That letter involved disease-related blog and social content rather than hidden sildenafil or tadalafil, but the monitoring lesson is similar. FDA reads the public-facing path, not only the bottle label.
For supplement teams, the useful monitoring list is concrete:
FDA recall postingshealth fraud notificationswarning lettersmarketplace listingssocial-to-store pathsrefund language
The strongest internal review starts with the same question a source monitor asks: what would an outside reviewer see? Product names, intended-use language, ingredient claims, social posts, third-party seller pages, consumer reviews, and affiliate funnels can all point toward the risk pattern before a formal FDA source appears.
FDA Warning Monitor is tracking this as a repeat supplement category, not a one-off recall. The practical value is not alarm. It is a cleaner habit: read the public source, note the product type and channel, compare it with recent warning letters, and decide whether the pattern belongs in your watchlist.
Get the weekly FDA source digest. It is a free weekly email with warning-letter, recall, and enforcement notes tied back to public FDA records.
Prefer LinkedIn? Follow FDA Warning Monitor for public FDA warning-letter, recall, and enforcement signals.
FDA's GLP-1 compounding crackdown
OTC drug CGMP warning-letter patterns
Browse source categories or read the latest archive.
FDA recall posting: Best Supplements Best Prices WAP Sensual Enhancement capsules, May 18, 2026
FDA: Sexual Enhancement and Energy Product Notifications
FDA: Information on Select Dietary Supplement Ingredients and Other Substances
FDA warning letter: OptiHealth Products, Inc., April 29, 2026